Linton Lifesciences Acquires 3D-Bioplotter Platform

The deal brings a two-decade-old bioprinting system from EnvisionTEC GmbH under Linton's biofabrication operations.

Updated on Nov. 22, 2026 in Healthcare

Isometric editorial illustration of a steel nozzle depositing a translucent hydrogel spiral onto a dish, evoking bioprinting technology.
Linton Lifesciences has acquired the 3D-Bioplotter bioprinting platform and its operations from EnvisionTEC GmbH, expanding its biofabrication work in regenerative medicine. AI Illustration. Upload story photo >

Linton Lifesciences has acquired the 3D-Bioplotter platform, along with its technology and operations, from EnvisionTEC GmbH. The system has been on the market for more than two decades and now sits alongside Linton's Boston headquarters and a German site in Gladbeck.

Why it matters

The acquisition gives Linton an established technology base, a global user community, and deep technical expertise as it builds out biofabrication capabilities for regenerative medicine. It also reflects how the EnvisionTEC business has changed hands since Desktop Metal's 2021 acquisition and subsequent Chapter 11 filing.

The 3D-Bioplotter has been on the market for more than two decades, while its prior owner, Desktop Metal, acquired EnvisionTEC in 2021 before filing for Chapter 11 in July 2025. The purchase price and post-deal revenue figures were not disclosed.

The players

Linton Lifesciences

A biofabrication company combining chemistry, robotics, and 3D bioprinting in a hybrid manufacturing workflow, headquartered in Boston and led by CEO Ricky Solorzano, who previously co-founded the bioprinter maker Allevi.

EnvisionTEC GmbH

A German 3D printer manufacturer based historically in Gladbeck, which was acquired by Desktop Metal in 2021 and later sold to an affiliate of Anzu Partners after Desktop Metal's Chapter 11 filing.

The details

The 3D-Bioplotter, a system from EnvisionTEC GmbH, was acquired by Linton Lifesciences along with its technology and operations. Linton will continue supporting the platform and its existing users while investing in the next generation of the system.

Timeline

  1. July 2025: Desktop Metal filed for Chapter 11, and Linton Lifesciences launched.

  2. April 2026: Linton introduced Biofabricated New Approach Methodologies (bfNAMs).

Market Landscape

The sale continues a pattern of consolidation in 3D bioprinting, where equipment originally developed by standalone firms has been absorbed into larger industrial groups and then resold. Linton's move positions the Bioplotter as both a research tool and a production platform for its own graft and tissue-model programs, rather than a standalone printer line.

For clinicians and researchers who rely on bioprinting equipment, the transfer means continued support for the 3D-Bioplotter and its user base under new ownership. Future product changes will come from Linton's planned next generation of the platform rather than from EnvisionTEC's former development path.

The takeaway

Ownership changes can reshape a long-established research tool, and for users of the 3D-Bioplotter, continuity of support and the direction of the next platform generation are the practical questions to watch.

Further reading

For broader context on how bioprinting is reshaping medical manufacturing, explore more in Healthcare.

Source note: This article includes information reported by VoxelMatters - The heart of additive manufacturing.